Blue Matter Blog

Location, Location, Location: Why You Need a Systematic Approach to Locating Your European HQ
March 17, 2020

Location, Location, Location:  Most regard that as the first rule of real estate.  Simply put, it refers to the fact that a home’s value can vary dramatically based solely on its location.  Nice neighborhood with good schools, low crime, and beautiful tree-lined streets? In a place like that, a home will command a much higher …

Europe’s Got Talent II: Deciding Who to Hire and When
March 3, 2020

When a non-EU-based biopharmaceutical company decides to establish a presence in Europe, there are seemingly countless items that need to be managed, ranging from the highly strategic to the mundane.  One of the most important items is building the European team.  In the previous article, we outlined five ways in which hiring and recruiting differ …

Europe’s Got Talent I: Five Ways Recruiting a Team in Europe Differs from the US
March 2, 2020

“Our people are our greatest asset.” That statement is a time-honored cliché in the business world.  However, clichés typically come about for a reason: They’re usually true.  No biopharmaceutical company can move into Europe without recruiting and hiring talent there.  Obviously, those are essential steps to building a local presence anywhere.  In this installment of …

Show Me the Value: Understanding the Payer Landscape and Engaging with Payers in Europe
February 24, 2020

Basic and Essential For any biopharma company planning an initial move into Europe, there are myriad issues to address, as this series outlines.  One of the most important is ensuring that a company’s product(s) will be reimbursed by the various national payers that exist throughout European markets.  It’s a basic truth:  Payers are vital to …

Europe is Not a Country: Defining the launch sequence and market-specific strategies for a diverse Europe
February 19, 2020

Why a Europe-Tailored Strategy is Important When a biopharmaceutical company decides to enter the “European market,” it’s important to recognize that Europe is not really a single market.  Aside from having the European Medicines Agency (EMA) as common regulatory body, the European Union (EU) is actually a combination of 27 markets, each with a differentiated …

File and Don’t Forget: Securing Intellectual Property Protection and Completing Regulatory Filings
January 20, 2020

When entering European markets, a biopharma company must do a range of important things, many of which we will address throughout this series. In this installment, we cover two foundational elements of any European market entry that can set the commercial playing field for years to come.  They are 1.) Securing intellectual property (IP) protection …

Blue Matter Breakfast Club Meeting #3 – A Discussion with Theresa Heggie of Alnylam Pharmaceuticals
November 8, 2019

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The third Breakfast Club meeting was on 5th November 2019 at Skylounge restaurant in Zug, Switzerland.  …

Seven Keys to Success in Europe
August 26, 2019

For US-based biopharmaceutical companies seeking to expand, establishing a presence in Europe is usually an obvious next step.  Investors typically expect that a company will avail itself of such a large market opportunity and unlock the full commercial value of its assets. Europe represents the second largest market in the world for prescription pharmaceuticals.  The …